FDA Gives BioMarin Pharmaceuticals' Hemophilia Gene Therapy Priority ReviewThe Motley Fool • 02/21/20
5 Goldman Sachs Conviction List Stocks With Massive Upside Potential for 202024/7 Wall Street • 01/10/20
BioMarin (BMRN) Up 11% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 11/22/19
BioMarin (BMRN) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 10/29/19